Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 28 for “"Mithramycin"”.
-
INTERACTIONS OF POST-PKS ENZYMES OF THE MITHRAMYCIN BIOSYNTHETIC PATHWAY
… catalyzed by MtmW, the final enzyme in the mithramycin (MTM) biosynthetic pathway, and to discover the interaction between MtmW and MtmOIV. MtmW is an aldol-ketoreductase responsible for reducing the most distal carbonyl on the MTM pentyl side chain. It forms an octamer that has structural …
-
ELUCIDATING MOLECULAR FUNCTION OF MITHRAMYCIN AND ANALOGUES FOR THE TREATMENT OF EWS-ETS EXPRESSING CANCERS
… of many drugs developed to treat the disease. Mithramycin (MTM) was identified as a potent inhibitor of EWS-FLI1, but despite its pre-clinical success there were serious toxicities associated with its use including hepatotoxicity. Adverse effects associated with MTM treatment resulted in …
-
INVESTIGATION OF THE MECHANISM OF ACTION FOR MITHRAMYCIN AND THE BIOSYNTHESIS OF L-REDNOSE IN SAQUAYAMYCINS
… later steps were unsuccessful. The aureolic acid mithramycin (MTM) was recently tested in clinical trials for Ewing sarcoma following the discovery of MTM as a potent inhibitor of the oncogenic transcription factor EWS-FLI1 present only in Ewing sarcoma cells It is understood that MTM binds the …
-
ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN BIOSYNTHETIC GENE CLUSTER AND ALTERING THE GLYCOSYLATION PATTERNS OF TETRACENOMYCINS AND MITHRAMYCIN-PATHWAY MOLECULES
… side chain and cross-linking of histone H. Mithramycin blocks transcription of proto-oncogenes c-myc and c-src by forming an Mg2+-coordinated homodimer in the GC-rich minor groove of DNA. The purpose of this research was to investigate the biosynthesis of several type II polyketide compounds …
-
Targeted Inhibition of Sp1 Transcription Factor and Anti-Angiogenesis of Human Pancreatic Cancer
… angiogenic genes expression were suppressed by mithramycin treatment both in vitro and in vivo. Moreover, mithramycin treatment reduced MVD in vivo. This was consistent with the down-regulation of VEGF, PDGF, and EGFR. Human xenograft pancreatic tumor growth was suppressed by Bevacizumab …
-
DEVELOPMENT OF MITHRAMYCIN ANALOGUES WITH IMPROVED EFFICACY AND REDUCED TOXICITY FOR TREATMENT OF ETS-DEPENDENT TUMORS IN EWING SARCOMA AND PROSTATE CANCER
… of oncogenic ETS transcription factor fusions. Mithramycin (MTM) has been identified as an inhibitor of EWS-FLI1 transcription factor, a gene fusion product responsible for oncogenesis in Ewing sarcoma. Despite preclinical success, a phase I/II clinical trial testing MTM therapy in refractory …
-
Molecular pathology of Birt-Hogg-Dubé Syndrome
… greatest inhibitory selectivity was induced by mithramycin in which a 10-fold difference between GI50 values in FLCN negative and positive UOK257 cells. Mithramycin was also shown to be more cytotoxic to FLCN negative cells than to FLCN-positive UOK257 cells by 10 fold (at 200nM), in clonogenic …
-
Cellular & Molecular Mechanisms That Contribute to the Early Development of Skeletal Muscle & Systemic Insulin Resistance
… treated high-fat fed mice with an Sp1 inhibitor, mithramycin. We found that mithramycin prevented SMM cholesterol accumulation and insulin resistance. This series of studies provide evidence that HBP/Sp1-mediated cholesterol accumulation in SMM is a causal, early and reversible mechanism of whole …
-
Regulation der konstitutiven VEGF-Sekretion in der Retinalen Pigmentepithel/Choroidea-Organkultur
… von HIF-1 - Stattic zur Hemmung von STAT3 - Mithramycin zur Hemmung von Sp1 - ein (biochemischer) NF-κB-Inhibitor - SB203580 zur Hemmung von p38 (MAPK) - SU1498 zur Hemmung einer rezeptorgebundenen Tyrosinkinase am VEGFR2 Getestet wurde innerhalb einer Organkultur mit präpariertem porcinem …
-
In vitro models for detection of hepatocyte toxicity induced by anti-cancer drugs
… their sensitivity to a known hepatotoxic drug (mithramycin), drugs used in clinical practice in colorectal cancer (oxaliplatin, 5-FU) and novel agents in preclinical development (ruthenium compounds). In order to characterise the cell models, morphology, growth parameters, and viability were …
-
Chemoenzymatic Studies to Enhance the Chemical Space of Natural Products
… structure-activity-relationship information. Mithramycin (MTM) is the most prominent member of the aureolic acid type anticancer agents. Previous work in our laboratory generated three MTM analogues, MTM SA, MTM SK, and MTM SDK by inactivating the mtmW gene. We developed new MTM analogues by …
-
INVESTIGATING STRUCTURE AND PROTEIN-PROTEIN INTERACTIONS OF KEY POST-TYPE II PKS TAILORING ENZYMES
… little has been done to study them. In the mithramycin (MTM) biosynthetic pathway the Baeyer−Villiger monooxygenase (BVMO) MtmOIV and the ketoreductase MtmW form one such enzyme pair that catalyze the final two steps en route to the final product. MtmOIV oxidatively cleaves the fourth ring …
-
Investigating novel treatment approaches to combat Clostridioides difficile
… scaffolds identified were those of mitomycin C, mithramycin A, aureomycin, NP-003875, NAT13-338148, NAT18-355531, and NAT18-355768. Of these, mithramycin A, aureomycin, and NP-003875 were also found to harbor anti-virulence properties as they inhibited toxin production by the pathogen. …
-
Μηχανισμοί μεταγραφικής ρύθμισης του γονιδίου του αναστολέα του κυτταρικού κύκλου p21WAF1/Cip-1 του ανθρώπου
… phosphorylation at serine 15. We also found that Mithramycin, a compound that is used for the treatment of Paget’s disease and in certain forms of cancer, has a dual effect on cells. On one hand, it strongly activates p53 by a similar mechanism to 5-FU i.e. by phosphorylation at serine 15. On the …
-
Δυναμική ταξινόμηση των μορφών της νόσου του Paget των οστών και η θεραπευτική αντιμετώπισή τους
… of complications, although calcitonin and mithramycin, within their limitations, have their indications in dealing with this peculiar but crippling disease.
-
Orally Administered Nanoscale Drug Delivery System for Colorectal Cancer
Mithramycin-A (Mit-A) is a US Food and Drug Administration (FDA) approved chemotherapeutic agent that is used for the treatment of testicular cancer. According to previous studies, Mit-A has shown promising results in targeting colorectal cancer (CRC) and cancer stem cells (CSCs) which are …
-
Επανεργοποίηση της έκφρασης της εμβρυϊκής αιμοσφαιρίνης με χημικές ουσίες σε in vitro και in vivo πειραματικά συστήματα
… drugs.Studies of the mechanism of action of mithramycin and oxamflatin showed that mithramycin causes a reduction in the binding of transcription factor Sp1 to selected regulatory regions of the Locus Control Region (LCR) and that oxamflatin causes an increase in the acetylation of regulatory …
-
New strategies for assessing the sequence selective binding of small molecules to DNA
… to bind to GpC; echinomycin (CpG), TANDEM (TpA), mithramycin (GpC, GpG) and the AT-selective minor groove binding ligands distamycin and Hoechst 33258. These ligands show large differences in their binding to tetranucleotides which contain the preferred dinucleotide steps. For example ACGT and …
-
Defining the Mode of Medulloblastoma Growth using the Ptch1 Heterozygous Mouse Model
… medulloblastoma cell growth. The aureolic acid mithramycin triggered Sox2+ cell apoptosis in vitro, blocked self-renewal and extended Ptch1+/- mouse survival in vivo, and completely prevented tumour regrowth in transplantation experiments. Therefore, targeting self-renewal in medulloblastoma by …
Page 1 of 2